Drug Profile


Alternative Names: Batimastat - British Biotech; BB 94; Collagenase inhibitors-1

Latest Information Update: 01 Jul 2002

Price : $50

At a glance

  • Originator British Biotech
  • Class Aromatic amino acids; Essential amino acids; Small molecules; Thiophenes
  • Mechanism of Action Angiogenesis inhibitors; Collagenase inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer; Malignant ascites; Pleural effusion

Most Recent Events

  • 27 Jul 1999 A study has been added to the therapeutic trials and adverse events sections
  • 27 Jul 1999 A preclinical study has been added to the pharmacodynamics section
  • 20 Dec 1996 Discontinued-III for Malignant ascites in United Kingdom (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top